Signal
In September 2025, scientists at Stanford University and the Arc Institute successfully used generative AI to design 16 entirely new viruses capable of killing E. coli bacteria. These viruses, or bacteriophages, were selected from 302 candidates generated by two in-house AI models, Evo 1 and Evo 2. Several of the designed phages replicated faster and more effectively than naturally occurring reference strains. The AI models were trained without exposure to human-infecting virus data, and researchers emphasised that translating these methods to target humans would not be trivial. Nonetheless, this marks the first time AI has authored viable, self-replicating biological code and then brought it to life.
Why it matters
This breakthrough moves biology from discovery to design. AI is now a creative agent in the life sciences, not just an analytical one. Therapeutically, this opens new frontiers for combating antibiotic-resistant bacteria and for accelerating synthetic biology applications. Strategically, it creates new vectors of risk. The tools used to design these phages could, in the wrong hands or with broader datasets, be turned toward harmful or destabilising purposes. Legacy biosecurity frameworks are not built to govern systems that write life as code. Regulatory guardrails like dataset restrictions are temporary and porous. As generative AI becomes more capable, biological sovereignty will depend on governance that can match the velocity of code-based creation.
Strategic takeaway
Generative biology is no longer speculative. AI can now author living systems. The Sixth Field must treat biology as code, not just chemistry. This requires a shift in doctrine: from controlling material flows to governing algorithmic assembly. Life is becoming a programmable domain.
Investor implications
Investors should monitor firms enabling AI-driven genome design, biosecurity audit pipelines, and synthetic biology platforms. Public companies like CRISPR Therapeutics (NASDAQ: CRSP), Beam Therapeutics (NASDAQ: BEAM), and Illumina (NASDAQ: ILMN) could benefit from growing interest in programmable biology. Biosecurity-focused ventures including firms specialising in genetic threat detection or safe-by-design genomic engineering may see increased capital inflow. Governments may expand funding for dual-use bio infrastructure, and regulatory-aligned firms will be favoured. Synthetic biology ETFs, such as the ARK Genomic Revolution ETF (ARKG), may rotate exposure to firms with embedded safeguards or sovereign trust.
Watchpoints
2025–26 → Scientific validation and peer review of the Stanford/Arc results
2026 → Policy responses on generative genome design and AI-authored life
Any demonstration of AI-designed human-affecting viral agents, even in lab-controlled settings
Tactical Lexicon: Genomic Generativity
The ability of AI systems to design and create viable, self-replicating genomes from scratch. Why it matters: It recasts biology as programmable infrastructure.
Relevance: It shifts sovereignty from the lab bench to the model weights.
Source: technologyreview.com
The signal is the high ground. Hold it.
Subscribe for monthly tactical briefings on AI, defence, DePIN, and geostrategy.
thesixthfield.com